Wetenschappelijk tijdschrift voor psychiaters, artsen in opleiding tot psychiater en andere geïnteresseerden
  • EN
  • NL
Tijdschrift voor Psychiatrie
  • Tijdschrift
  • Terug naar hoofdmenu
    New articles Current issue Previous issues Special issues Book reviews
    Auteursrichtlijnen Over het tijdschrift Redactie Abonnementen Colofon Adverteren
    Current issue
    Nummer 8 / 2023 Jaargang 65
    Tijdschrift voor Psychiatrie
    8 / 2023

    Current issue
  • Accreditatie
  • Meetinstrumenten
  • Vacatures
Edit
  • EN
  • NL
  1. Home
  2. Artikelen
  3. CYP2D6 and CYP2C19 genotyping: effectivity...
Thesis article

CYP2D6 and CYP2C19 genotyping: effectivity in psychiatric practice

A.B. Koopmans, D.J. Vinkers, H.W. Hoek, P.N. van Harten

Background International guidelines recommend in patients with an in- or decreased CYP2D6 and CYP2C19 metabolism to adjust the dose of medication metabolized by these enzymes. This is in purpose to increase effectiveness and to lower the risk of side-effects of this medication. However, it is still unclear if dose adjustment based on genotype results in better clinical outcomes.
Aim To provide an update regarding CYP2D6 and CYP2C19 genotyping in psychiatry in relation to ethnic diversity.To provide an update regarding CYP2D6 and CYP2C19 genotyping in psychiatry in relation to ethnic diversity.
Method We conducted a comprehensive meta-analysis to the prevalence of non-normal metabolizers as the equivalent of the sum-prevalence of poor, intermediate and ultrarapid metabolizer CYP2D6 and CYP2C19 predicted phenotypes. For the prevalence and effectiveness study, a total of 166 Antilleans living in the Netherlands and 269 psychiatric patients (on the island CuraƧao) were genotyped for CYP2D6 and CYP2C19. Of the psychiatric patients, 45 non-normal CYP2D6 metabolizers using medication metabolized by CYP2D6, were included for dose adjustment and were matched with 41 normal metabolizers. All 45 patients were using antipsychotic medication for a minimum of two years. Four months after dose adjustment they were reassessed.
Results The mean total probability estimates of having a non-normal predicted phenotype worldwide were 36% and 62% for CYP2D6 and CYP2C19, respectively. There was a large interethnic variability (min-max 2.7-61.2% (CYP2D6) and minmax 31.7-80.1% (CYP2C19)). No significant difference was found in the phenotypes of psychiatric patients, Dutch Caribbean subjects from the general population, and European populations. There were no beneficial effects of dose adjustments to phenotype in the non-normal CYP2D6 metabolizers.
Conclusion More than 75% of the world population has a non-normal CYP2D6 and/or CYP2C19 phenotype. Dose adjustment to the CYP2D6 phenotype according to international guidelines in patients on long-term antipsychotic treatment showed no beneficial effect. Further research to CYP genotyping in psychiatry is warranted.

Download PDF
Twitter Facebook LinkedIn Mail WhatsApp
Published by the Stichting Tijdschrift voor Psychiatrie on behalf of the Nederlandse Vereniging voor Psychiatrie and the Vlaamse Vereniging voor Psychiatrie.

Over TvP

Over het tijdschrift Redactie Auteursrichtlijnen Colofon
Abonnementen Abonnee worden Adverteren

Contact

Redactiebureau Tijdschrift voor Psychiatrie
drs. S.L. (Lianne) van der Meer
Telefoon: 030 899 00 80
info@tijdschriftvoorpsychiatrie.nl

Copyright

Redactie en uitgever zijn niet aansprakelijk voor de inhoud van de onder auteursnaam opgenomen artikelen of van de advertenties. Niets uit dit tijdschrift mag openbaar worden gemaakt door middel van druk, microfilm of op welke wijze ook, zonder schriftelijke toestemming van de redactie.

© copyright 2023 Tijdschrift voor Psychiatrie